UK firm joins a European consortium involved in the Psoriasis Anti-Inflammatory Treatment (PAT) project
Pharmaceutical formulation development and manufacturing services provider Molecular Profiles, which was recently acquired by Boston, MA, US-based Columbia Laboratories, has been selected as the formulation development partner for a pan-European project.
The UK-based firm has been chosen by Swiss clinical stage biopharmaceutical company Telormedix to develop both topical and solid dosage formulations for the use in the treatment of psoriasis.
The project, operating under the acronym PAT (Psoriasis Anti-inflammatory Treatment), will involve other consortium partners Biopta, Midatech Biogune and the University Hospital Zurich.
Telormedix raised funding from the European Eurostars Programme to coordinate this international research project for one of its promising drug candidates, TMX-302, which will use Midatech’s glycan-coated gold nanoparticles formulated using Molecular Profiles’ expertise.
Johanna Holldack, CEO at Telormedix, said: 'We are absolutely delighted to have secured this funding with such a world class consortium to bring TMX-302 to pre-clinical proof of concept. The team at Molecular Profiles will play a key role in developing new oral and topical formulations of TMX-302, both of which are viewed as practicable administration options for the treatment of psoriasis.'
The deal comes just weeks after Molecular Profiles opened its new facility following a successful inspection from the UK's Medical and Healthcare products Regulatory Agency (MHRA).
Molecular Profiles’ Chief Executive Nikin Patel added: 'Our team is ready to apply our technologies to deliver a robust topical and oral formulation.
'We anticipate that this is just the start of a longer-term clinical development and manufacturing initiative to support a future trial. Beyond the formulation work, our new facility gives Telormedix the reassurance we can also support their finished dosage form production requirements.'
Molecular Profiles’ specialises in advanced characterisation, pre-clinical and clinical development, clinical manufacturing and analytical support. Its early-stage services extend from pre-formulation, formulation development and solid-state screening with specialist knowledge on developing challenging molecules.